Haojun Ouyang

Publications by Year

Research Areas

Neurogenetic and Muscular Disorders Research, RNA modifications and cancer, RNA Interference and Gene Delivery, Pluripotent Stem Cells Research, Gastric Cancer Management and Outcomes

Most-Cited Works

• → Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial(2021)456 cited
• → Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial(2021)241 cited
• → Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study(2017)103 cited
• → Onasemnogene Abeparvovec-xioi Gene-Replacement Therapy for Spinal Muscular Atrophy Type 1 (SMA1): Phase 3 US Study (STR1VE) Update (1828)(2020)19 cited
• → Contributors to the substantial variation in on‐treatment testosterone levels in men receiving transdermal testosterone gels in randomized trials(2017)14 cited
• → A Phase 2, Placebo-Controlled Study of the Opioid Receptor Antagonist LY2196044 for the Treatment of Alcohol Dependence(2013)13 cited
• → Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors(2015)12 cited
• → Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): Long-term follow-up from the onasemnogene abeparvovec phase 1/2A clinical trial(2019)5 cited
• → O-007 Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study(2016)5 cited
• → Gene-Replacement Therapy in Spinal Muscular Atrophy Type 1: Long-Term Follow-Up From the Onasemnogene Abeparvovec-xioi Phase 1/2a Clinical Trial (1808)(2020)4 cited